Abstract

Alveolar bone grafting is considered to be one of the most challenging task in the management of cleft lip and palate patients as it is expected to bridge the gap between the alveolar segments and provide the solid base for the un-erupted tooth/teeth to erupt through it, besides effectively healing the Oro-antral fistula if any passing through the cleft into the nasal cavity. Although the traditional approach is to use autogenous bone graft from iliac crest, which has its own side-effects like pain, morbidity, additional surgery, etc. However with the advent of Tissue engineering technique, it has become possible to overcome most of these challenges by using a tissue friendly yet innovative material by name CGF (Concentrated Growth Factor) which in reality is the latest version of platelet-rich plasma having in it abundant of growth factors thereby serving the purpose of a regenerative medicine, wherein three factors are important to stimulate the bone regenerative effect: 1) Scaffold 2) Growth factors and 3) Autologous cells. All these are found to be present in sufficient quantity in CGF which was first introduced by Sacco in 2006 followed by Corigliano in 2010.